In the treatment-naïve AML patients, the CR + CRi rates were 45% and in the R/R setting, the CR + CRi rates were 47% in those without prior HMA/HD1 inhibitor therapy, 38% with prior HMA/HD1 inhibitor therapy, and 30% with prior IDH1 inhibitor therapy [40]. The gene discussed is IDH1; the disease is acute myeloid leukemia.